Published in
Elsevier, European Journal of Cancer, (69), p. 9-18, 2016
DOI: 10.1016/j.ejca.2016.09.021
Links
Tools
Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.
Journal article published in 2016 by
Maria E. Goossens 
,
Maurice P. Zeegers,
Hendrik van Poppel ,
Steven Joniau,
Koen Ackaert,
Filip Ameye ,
Ignace Billiet,
Johan Braeckman,
Alex Breugelmans ,
Jochen Darras,
Kurt Dilen,
Lieven Goeman,
Bertrand Tombal,
Siska Van Bruwaene,
Ben Van Cleyenbreugel
and other authors.
,
Maurice P. Zeegers,
Hendrik van Poppel ,
Steven Joniau,
Koen Ackaert,
Filip Ameye ,
Ignace Billiet,
Johan Braeckman,
Alex Breugelmans ,
Jochen Darras,
Kurt Dilen,
Lieven Goeman,
Bertrand Tombal,
Siska Van Bruwaene,
Ben Van Cleyenbreugel
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
In Belgium, bladder cancer (BC) is the fifth most common cancer in men. The per-patient lifetime cost is high. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of BC. We therefore hypothesised that selenium may be suitable for chemoprevention of recurrence of BC.